Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07228637 | Pursuing Exploration Into the Supportive Care Needs and Intervention Preferences of Survivors of Testicular Cancer(PERSIST) | active not recruiting | N/A | 70 | Indiana UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01742403 | Continuous Monitoring of Prostate Position During Radiotherapy(KIM Gating) | active not recruiting | N/A | 100 | Royal North Shore HospitalOTHER | 1 | Feb 6, 2026 |
| clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT03902951 | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | active not recruiting | Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04455750 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy(CASPAR) | active not recruiting | Phase 3 | 61 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05737199 | Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | active not recruiting | Phase 2 | 21 | Niigata University Medical & Dental HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07354087 | Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry(IMPACTEndoAsia) | active not recruiting | — | 300 | Tata Memorial HospitalOTHER_GOV | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT03615599 | Plant-based Diets and Risk of Cancer in the Adventist Health Study-2(AHS-2) | active not recruiting | — | 96,000 | Loma Linda UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05043922 | A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | active not recruiting | Phase 2 | 93 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT01936883 | Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy(BrachyQOL) | active not recruiting | N/A | 195 | British Columbia Cancer AgencyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02312401 | Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy | active not recruiting | Phase 2 | 120 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03386045 | Optimal Prostate Study | active not recruiting | N/A | 503 | Royal North Shore HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03426748 | LDR vs. HDR Brachytherapy for Prostate Cancer(LDR/HDRmono) | active not recruiting | N/A | 140 | British Columbia Cancer AgencyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06483997 | Diet, Hepcidin, and Chemotherapy RDI | active not recruiting | — | 100 | George Washington UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03984695 | Sexual Health Empowerment for Women's Health(SHE-WOMEN) | active not recruiting | N/A | 279 | University of Kansas Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04169997 | A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer(FLAMES) | active not recruiting | Phase 3 | 404 | Impact Therapeutics, Inc.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05786456 | e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study | active not recruiting | N/A | 23 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06051942 | PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs | active not recruiting | N/A | 125 | PROCEPT BioRoboticsINDUSTRY | 4 | Jan 28, 2026 | clinicaltrials |
| NCT07352748 | Exploiting Heterogeneity in Hormone Therapy Response to Reveal Early Determinants of Drug Resistance in Advanced PCa(MOSAIC) | active not recruiting | — | 30 | Universita di VeronaOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT02658565 | Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation | active not recruiting | N/A | 401 | Frederick R. Ueland, M.D.OTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05761912 | Application of Ultrasound Radiomics in Ultrasound Fusion Targeted Prostate Biopsy | active not recruiting | — | 464 | Shanghai Minhang Central HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04576104 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | active not recruiting | Phase 2 | 51 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05327452 | Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study | active not recruiting | N/A | 135 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02914873 | SPCG17: Prostate Cancer Active Surveillance Trigger Trial(PCASTT) | active not recruiting | N/A | 2,008 | Uppsala UniversityOTHER | 5 | Jan 20, 2026 | clinicaltrials |
| NCT03937843 | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma | active not recruiting | Phase 2 | 135 | Swiss Cancer InstituteOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT05301114 | Social Risk Factors and Discrimination in Cancer Survivorship | active not recruiting | N/A | 1,116 | Medstar Health Research InstituteOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06411938 | A Cervical Cancer Prevention Program in Kenya(Merck-3) | active not recruiting | N/A | 2,300 | Indiana UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06796738 | Advancing Cervical Cancer Screening Through the Emergency Department - IIS | active not recruiting | N/A | 200 | University of RochesterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05924672 | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | active not recruiting | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04647526 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment(SPLASH) | active not recruiting | Phase 3 | 455 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 6 | Jan 13, 2026 | clinicaltrials |
| NCT06238635 | Dostarlimab and Cobolimab in Advanced Cervical Cancer | active not recruiting | Phase 2 | 66 | Meghan SheaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02454543 | Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases(g-RAMPP) | active not recruiting | N/A | 452 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04269512 | Role of Lymphnode Dissection in Men With Prostate Cancer Treated With Radical Prostatectomy(PREDICT) | active not recruiting | N/A | 3,650 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05902520 | Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors(ACT) | active not recruiting | Phase 1 | 18 | AgonOx, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03794635 | An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer | active not recruiting | N/A | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04204811 | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | active not recruiting | N/A | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05010200 | The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.(PGV-Prostate) | active not recruiting | Phase 1 | 27 | Ashutosh Kumar TewariOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03017794 | Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy | active not recruiting | — | 118 | Mayo ClinicOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03955978 | TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer | active not recruiting | Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05416424 | Life Study: Lifestyle Intervention in Fibroid Elimination | active not recruiting | N/A | 100 | NYU Langone HealthOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06416696 | Toripalimab for High-risk Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT01643954 | Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at The James | active not recruiting | N/A | 1,531 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 9, 2026source: clinicaltrials